Complex of hydroxyl(thio)pyrone & hydroxyl(thio)pyridinone with Zn(II) & Mo(IV) Thermodynamic stability & insulin-mimetic activity

Complexes of hydroxy(thio)pyrone and hydroxy(thio)pyridinone with Zn(II) and Mo(VI). Thermodynamic stability and insulin-mimetic activity†

Sílvia Chaves,[a] Ratomir Jelic,[ab] Catarina Mendonça,[a] Marta Carrasco,[a] Yutaka Yoshikawa,[c] Hiromu Sakurai[d] and M. Amélia Santos*[a]

The development of metal-containing pharmaceuticals as insulin-mimetics has been the object of recent worldwide research. We have examined a series of zinc(II) and molybdenum(VI) complexes with model O,S-donor ligands (thiomaltol and 1,2-dimethyl-3-hydroxypyridine-4-thione (DMHTP)) and the corresponding O,O-analogues (maltol and DMHP) for their insulin-mimetic activity. Aimed at getting structure-activity relationships, some physical-chemical properties were also studied, such as metal-complex formation, speciation at different pH conditions and ligand lipophilicity. The Zn-complexes exhibit considerably higher insulin-mimetic activity than the corresponding Mo-analogues. Particularly, the bis(thiomaltolato)zinc(II) complex reveals a very high activity, ascribed to the effect of the thione π character and to the soft nature of the sulfur donor atom enhancing the Zn(II)–ligand affinity and the ligand/complex lipophilicity, two determinant parameters for delivering the metal-drug into the cells. Hence, these preliminary studies indicate that the Zn(thiomaltol)$_2$ complex can be considered a potential drug candidate for treatment of diabetes mellitus, upon *in vivo* evaluations.

1. Introduction

Diabetes mellitus (DM) is one of the most widespread diseases in the world. Type 1 DM can be controlled only by daily injections of insulin, while type 2 is treated by several types of synthetic therapeutics. Due to drawbacks associated with currently available treatments, DM is an important target in drug development and several metal-containing drug candidates have been recently studied.[1,2]

Vanadium-containing complexes have by far been the metal complexes mostly tested both *in vitro* and *in vivo* as potential therapeutic agents for oral treatment of DM.[1–4] However, due to the non-established essentiality and also to some toxicity of vanadium (UL – tolerable upper intake level – VO^{2+} 1800 μg/day for humans),[5] a range of other metal (*e.g.* zinc, chromium, molybdenum, cobalt) complexes has been also tested as potential alternatives or coadjuvants of anti-hyperglycemic drugs for treating DM and associated metabolic syndromes.[1,3] Among those metal-containing drug candidates, a special emphasize can be given to the Zn(II) and Mo(VI) compounds.

In fact, zinc is an essential element (UL 40 mg/day)[5] with structural and functional roles in proteins and life processes and zinc complexes have been the mostly recently tested compounds for their anti-diabetic properties.[1,2] On the other hand, molybdenum and vanadium oxo-ions present quite a number of similarities, namely in terms of electronic configuration and ability for the inactivation of glycogen synthase,[1] besides displaying synergistic stimulation of glucose uptake in rat adipocytes in the presence of H$_2$O$_2$;[6,7] however, as compared with vanadium, molybdenum is an essential element with some toxicity (UL MoO$_2^{2+}$ 2000 μg/day)[5] that is present in the active site of several human enzymes (oxidases), thus possessing a considerably high bio-relevance.[8,9] To guarantee the bioavailability and the non-toxicity of metallodrugs, they should be administered as metal-complexes with low molecular weight, neutral charge and adequate lipo/hydrophilic and thermodynamic properties. In fact, to deliver a metal-complex to a specific site of action, besides the above referred properties to ensure bioavailability and efficient membrane-crossing ability, the thermodynamic stability of the complex is also an important factor because the ligand carrier is in contact with endogenous ligands (*e.g.* albumin and transferrin) which can compete for the metal ion.[10]

The 3-hydroxy-4-pyrone and –pyridinone compounds, in particular maltol (3-hydroxy-2-methyl-4-pyrone) and its *N*-derivative analogue deferriprone (3-hydroxy-2-methyl-4-pyridinone), are heterocyclic bidentate chelators, which have been particularly attractive for pharmaceutical purposes, mostly for iron and aluminium decorporation.[11–13] Due to their small molecular weight, non-toxicity, commercial availability or easy feasibility, as well as their ability to form stable neutral complexes, they have also been considered suitable to

[a] *Centro de Química Estrutural, Instituto Superior Técnico, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal. E-mail: masantos@ist.utl.pt; Fax: +351-21-8464455; Tel: +351-21-8419273*
[b] *Faculty of Science, Chemistry Department, Kragujevac, Serbia and Montenegro*
[c] *Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, 5 Nakauchy-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan*
[d] *Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minami-Tamagaki-cho, Suzuka, Mie 513-8670, Japan*
† Electronic supplementary information (ESI) available: Fig. S1, Fig. S2. See DOI: 10.1039/b914169c

deliver zinc into cells,[14] and their complexes with vanadium,[15] zinc[16] and molybdenum[17] have proved insulin mimetic activity. Comparison of the oral activity of several bis(maltolato)-metal complexes in animal models has shown that the most effective compounds, involving non-essential and essential metal ions, were the complexes with oxovanadium(IV) and dioxomolybdenum(VI), respectively.[1]

Despite the considerable number of solution and *in vivo* studies related with insulin mimetic properties of several metal ion (vanadium, zinc or molybdenum) complexes with (*O,O*) chelators, namely hydroxy-pyrone and –pyridinones,[1,16,17] a few recent studies are known with the corresponding thio derivatives containing (*O,S*) donor atoms,[10] some of them appearing while this manuscript was in progress.[18] Herein we present preliminary results of *in vitro* studies on anti-diabetic activity as well as solution equilibrium studies for the characterization (stoichiometry, thermodynamic stability, speciation) of Zn(II) and Mo(VI) complexes of (*O,S*) donor ligands, 3-hydroxy-4-thiopyrone (thiomaltol) and 3-hydroxy-2-methyl-4-thiopyridinone (DMHTP). These studies are also compared with the corresponding results obtained for the oxo-analogues (maltol and DMHP, see Scheme 1), aimed at shedding some light on structure activity relationships.

2. Experimental

2.1 Reagents and materials

All the chemicals were of analytical reagent grade and used as supplied without further purification. Whenever necessary, the organic solvents were dried according to standard methods.[19] Chemical reactions were monitored by TLC, using alumina plates coated with silica gel 60 F$_{254}$ (Merck). DMHP (1,2-dimethyl-3-hydroxy-4-pyridinone) and maltol (3-hydroxy-2-methyl-4-pyranone) were purchased from Aldrich; thiomaltol and DMHTP were synthesized in our laboratory.[20] In the complexation studies, the ZnCl$_2$ (0.0156 M) solution from Merck was standardized by titration with K$_2$H$_2$EDTA (EDTA ≡ ethylenediaminetetraacetic acid).

2.2 Apparatus

Melting points were measured with a Leica Galen III hot stage apparatus and are uncorrected. IR spectra were recorded on a Bio-Rad Merlin, FTS 3000 MX. The ^{1}H NMR spectra were recorded on a Bruker Advance II 400 spectrometer at 25 °C. Chemical shifts (δ) are reported in ppm, using tetramethylsilane (TMS) as reference. The following abbreviations are used: s = singlet, d = doublet. Elemental analyses were performed on a Fisons EA1108 CHNF/O instrument. The potentiometric equipment used was according to that previously described.[21]

2.3 Procedures

2.3.1 Synthesis of the complexes

Zn–maltol complex. Maltol (0.15 g, 1.2 mmol) was suspended in water (7 mL) and dissolved by the addition of 1 M KOH solution (0.6 mL; 1.2 mmol). Zn(NO$_3$)$_2$·4H$_2$O (0.155 g, 0.6 mmol) was added to the reaction mixture, which was left stirring for 2 h at room temperature. There was formation of a white precipitate, which was filtered, washed with cold water and recrystallized from ethanol to yield a white powder (66%); mp 238–239 °C. IR (KBr) 1616 cm^{-1} ($\nu_{C=O}$). ^{1}H-NMR (MeOD/TMS): 7.95 (d, 1 H, H-Py), 6.54 (d, 1 H, H-Py), 2.36 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{12}$H$_{10}$O$_6$Zn: C, 45.66; H, 3.17. Found: C, 45.21; H, 3.30.

Zn–DMHP complex. DMHP (0.15 g, 1 mmol) was suspended in water (7 mL) and dissolved by the addition of a 0.1 M HCl solution. Zn(NO$_3$)$_2$·4H$_2$O (0.131 g, 0.5 mmol) was added to the reaction mixture. A 0.1 M KOH solution was added until pH 7 and the mixture was left stirring for 2 h. There was formation of a white precipitate, which was filtered and washed with cold water and subsequently recrystallized from methanol to obtain the pure product as white powder (60%); mp: > 350 °C. IR (KBr) 1605 cm^{-1} ($\nu_{C=O}$). ^{1}H-NMR (MeOD/TMS): 7.36 (d, 1 H, H-Py), 6.41 (d, 1 H, H-Py), 3.72 (s, 3 H, CH$_3$), 2.40 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{14}$H$_{16}$N$_2$O$_4$Zn·0.7H$_2$O: N, 8.16; C, 48.95; H, 5.07. Found: N, 8.22; C, 48.57; H, 4.90.

Zn–thiomaltol complex. As described for Zn–maltol complex. Yield: 87% (0.106 g); mp > 350 °C. IR (KBr) 1576 cm^{-1} ($\nu_{C=S}$). ^{1}H-NMR (DMSO/TMS): 8.22 (d, 1 H, H-Py), 7.66 (d, 1 H, H-Py), 2.48 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{12}$H$_{10}$O$_4$S$_2$Zn: C, 41.45; H, 2.90; S, 18.44. Found: C, 41.10; H, 2.82; S, 18.26.

Zn–DMHTP complex. As described for Zn–DMHP complex. Yield: 84% (0.071 g); mp: 327–330 °C. IR (KBr) 1587 cm^{-1} ($\nu_{C=S}$). ^{1}H-NMR (DMSO/TMS): 7.50 (d, 1 H, H-Py), 7.39 (d, 1 H, H-Py), 3.89 (s, 3 H, CH$_3$), 2.47 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{14}$H$_{16}$N$_2$O$_2$S$_2$Zn: N, 7.63; C, 44.03; H, 4.22; S, 16.79. Found: N, 7.23; C, 43.92; H, 4.24; S, 17.24.

Mo–maltol complex. To a solution of maltol (0.1 g, 0.79 mmol) in ethanol (7 mL), an aqueous solution (11 mL) of ammonium molybdate (0.245 g, 0.2 mmol) was added. A 0.1 M HCl solution was added until pH 3.5 and left stirring for 6 h. The orange precipitate was filtered and washed three times

Scheme 1 Structural formulae of the ligands.

with water, ethanol and ether. Recrystallization from ethanol gave the pure complex as orange solid (89%); mp: 347–349 °C. IR (KBr) 1617 cm^{-1} ($\nu_{C=O}$). ^{1}H-NMR (MeOD/TMS): 8.24 (d, 1 H, H-Py), 6.79 (d, 1 H, H-Py), 2.47 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{12}$H$_{10}$MoO$_8$.5HCl: C, 25.72; H, 1.80. Found: C, 25.72; H, 1.66.

Mo–DMHP complex. To a solution of DMHP (0.1 g, 0.7 mmol) in hot water (7 mL), an aqueous solution (11 mL) of ammonium molybdate (0.44 g, 0.35 mmol) was added. A 0.1 M HCl solution was added until pH 4 and left stirring for 3 h. The yellow precipitate obtained was filtered off and washed three times with water, ethanol and ether. The pure complex was obtained as a yellow solid. Recrystallization from ethanol yielded the final product as yellow crystals (87%); mp > 350 °C. IR (KBr) 1616 cm^{-1} ($\nu_{C=O}$). ^{1}H-NMR (DMSO/TMS): 7.82 (d, 1 H, H-Py), 7.41 (d, 1 H, H-Py), 3.81 (s, 3 H, CH$_3$), 2.37 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{14}$H$_{16}$MoN$_2$O$_6$·1.5H$_2$O: N, 6.50; C, 38.99; H, 4.44. Found: N, 6.39; C, 39.00; H, 4.01.

Mo–thiomaltol complex. As previously described.[20] Yield: 30% (0.013 g); mp: decomposed before melting. IR (KBr) 1572 cm^{-1} ($\nu_{C=S}$). ^{1}H-NMR (MeOD/TMS): 8.46 (d, 1 H, H-Py), 7.68 (d, 1 H, H-Py), 2.44 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{12}$H$_{10}$MoO$_6$S$_2$·0.2H$_2$O: C, 35.13; H, 2.46; S, 15.63. Found: C, 34.82; H, 2.53; S, 15.50.

Mo–DMHTP complex. To a solution of DMTHP (0.03 g, 0.20 mmol) in ethanol (2 mL), an aqueous solution (3 mL) of ammonium molybdate (0.124 g, 0.1 mmol) was added. After 1 h stirring the yellow precipitate was filtered off and washed three times with water, ethanol and ether. Recrystallization from ethanol gave the pure complex as a dark yellow solid (65%); mp: > 230 °C. IR (KBr) 1600 cm^{-1} ($\nu_{C=S}$). ^{1}H-NMR (MeOD/TMS): 7.79 (d, 1 H, H-Py), 7.18 (d, 1 H, H-Py), 3.98 (s, 3 H, CH$_3$), 2.79 (s, 3 H, CH$_3$). Elemental analysis calc (%) C$_{14}$H$_{16}$MoN$_2$O$_4$S$_2$: N, 6.42; C, 38.53; H, 3.70; S, 14.70. Found: N, 6.05; C, 38.10; H, 3.28; S, 14.35.

2.3.2 Potentiometric titrations

Titrant solution. The titrant (0.1 M KOH) was prepared from a carbonate-free commercial concentrate (Titrisol), standardized by potentiometric titration with potassium hydrogen phthalate and discarded whenever the percentage of carbonate (Gran's method)[22] was about 0.5% of the total amount of base.

Measurements. Potentiometric titrations of the ligands and their zinc complexes in 15% (v/v) CH$_3$OH/H$_2$O solution were performed at ionic strength (I) 0.1 M KCl and 25.0 ± 0.1 °C. For all the samples prepared, the total volume was 20 mL, the ligand concentration was 2.0–4.0 × 10^{-3} M and the metal ion-to-ligand molar ratio was 0 : 1, 1 : 1, 1 : 2 or 1 : 4. Under the experimental conditions used, the value determined for the water ionisation constant (pK_w) was 13.84.

Calculation of equilibrium constants. The stepwise protonation constants, $K_i = [H_iL]/[H_{i-1}L][H]$, were previously determined by us.[20] The overall metal-complex stability constants, $\beta_{M_mH_hL_l} = [M_mH_hL_l]/[M]^m[H]^h[L]^l$, for the Zn(II) systems with thiomaltol,

DMHP and DMHTP were calculated by fitting the respective potentiometric data with the HYPERQUAD 2003 program.[22] The Zn(II) hydrolytic species[23] were included in the equilibrium model and the species distribution curves were plotted with the HYSS program.[22]

2.3.3 Partition coefficients

The octanol–water partition coefficients of the ligands were determined by the "shakeflask" method,[24] based in the concentration ratio of each compound between 1-octanol and a TRIS buffered aqueous phase at the physiological pH (7.4), both phases being previously pre-saturated with respect to each other. The species concentrations were evaluated by spectrophotometry, using the benzenoid bands of the ligands.

2.3.4 *In vitro* insulin-mimetic activity[25]

Male Wistar rats were sacrificed under anaesthesia with ether. The adipose tissues were removed, chopped with scissors and digested with collagenase for 60 min at 37 °C in Krebs Ringer bicarbonate buffer (120 mM NaCl, 1.27 mM CaCl$_2$, 1.2 mM MgSO$_4$, 4.75 mM KCl, 1.2 mM KH$_2$PO$_4$, 24 mM NaHCO$_3$: pH 7.4), containing 2% BSA. The obtained adipocytes were then separated from undigested tissues by filtration through nylon mesh and washed three times. The Zn and Mo complexes or ligands were dissolved in saline at various concentrations (final concentrations: 0.1, 0.5, 1, and 2 mM); 6 µL of each solution, 24 µL of saline and 15 µL of glucose (final concentration 5 mM) were added to 240 µL of the isolated adipocytes, and the resulting suspensions were incubated at 37 °C for 30 min. Finally, 15 µL of epinephrine solution (final concentration 10 µM) was added to the reaction mixtures, and the resulting solutions were incubated at 37 °C for 180 min. Soaking in ice water stopped the reactions and the mixtures were centrifuged at 3000 rpm for 10 min. FFA levels in the outer solution of the cells were determined using an FFA kit (NEFA C-test WAKO, Wako Pure Chemicals). *In vitro* insulin-mimetic activities of the complexes and ligands were evaluated by the IC$_{50}$ value, which defines the concentration of the complexes and ligands required for 50% inhibition of FFA release from the isolated rat adipocytes treated with epinephrine.

All animal experiments in the present study were approved by the Experimental Animal Research of Kyoto Pharmaceutical University (KPU) and were performed according to the Guideline for Animal Experimentation of KPU.

3. Results and discussion

3.1 Physical-chemical characterization of the compounds

The protonation constants of maltol, thiomaltol, DMHP and DMHTP were previously determined by us from spectrophotometric titrations in 15% (v/v) MeOH aqueous solutions, at 25 °C and 0.1 M KCl, except for DMHTP, which log K_2 (<2) was determined by ^{1}H NMR titration.[20] Spectrophotometric methods were also adopted in previous studies on Mo(VI) complexation because, under the usual potentiometric concentration conditions (mM), precipitation occurred.[20] The fully protonated forms of the studied compounds have one (maltol and thiomaltol) or two (DMHP and

Table 1 Stepwise protonation constants (log K_i) of maltol, thiomaltol, DMHP and DMHTP, as well as partition coefficients of the ligands and global formation constants of their Zn(II) and Mo(VI) complexes (I = 0.1 M KCl, 15% (v/v) CH$_3$OH/H$_2$O, T = 25.0 ± 0.1 °C)

Compound	Maltol	Thiomaltol	DMHP	DMHTP
log K_1	8.67(3)[a]	8.27(1)[a]	9.82(1)[a]	9.70(1)[a]
	8.67(3)[b]	8.16(2)[d]	9.77(2)[c]	9.47[d]
log K_2	8.44(2)[c]	8.12(2)[e]	3.74(2)[a]	9.44(1)[e]
	—		3.67(2)[c]	0.95(3)[f]
log P[g]	−0.04	0.54	−0.85	−0.59
	0.60[i]		−1.03[h]	
log β_{ZnL}	5.57(2)[c]	7.05(3)	7.35(1)	9.00(1)
			7.24(2)[c]	
log β_{ZnL2}	10.29(2)[c]	13.92(5)	13.69(1)	17.09(7)
			13.55(2)[c]	
log β_{ZnL3}	12.71(8)[c]	16.7(1)	—	20.53(5)
			15.2(2)[c]	
log $\beta_{ZnL2H-1}$	−0.1(1)[c]	—	2.62(3)	6.82(6)
			2.3(3)[c]	
pZn[j]	**6.1**	**7.9**	**6.3**	**8.4**
log $\beta_{MoO_2L_2}$[a]	38.51(5)	38.50(3)	39.31(4)	41.48(6)
			40.22(4)[l]	
log β_{MoO_3L}[a]	20.71(6)	21.19(3)	20.10(4)	21.82(5)
			20.0(1)[l]	
pMo[j]	**6.15**	**6.57**	**6.00**	**6.18**

[a] Ref. 20 (I = 0.10 M KCl, T = 25 °C, in 15% MeOH/H$_2$O); [b] ref. 26 (I = 0.16 M NaCl, T = 37 °C, in water); [c] ref. 27 (I = 0.20 M KCl, T = 25.0 °C, in water); [d] ref. 28 (I = 0.10 M KCl, T = 25.0 °C, in water); [e] ref. 29 (I = 0.16 M NaCl, T = 25.0 °C, in water); [f] ref. 20 determined by ^{1}H NMR titration; [g] in 1-octanol/water; [h] ref. 30; [i] ref. 31, in chloroform/saline system; [j] pM values (C_M = 10^{-6} M, C_L = 10^{-5} M, pH = 7.4); [l] ref. 32 (I = 0.2 M KCl, T = 25.0 °C, in water).

DMHTP) dissociable protons and the corresponding protonation constants (see Table 1) are according with the values typically attributed to the corresponding hydroxyl and N-pyridinyl groups.[12] Table 1 shows also that the stepwise protonation constants determined in our laboratory are in good agreement with some literature data,[20,26–29] obtained under different experimental conditions. Especially relevant is the fact that the hydroxyl protons of thiomaltol and DMHTP (8.27, 9.70) are considerably more acidic (lower log K_1) than the respective oxo-derivatives (8.67, 9.82), which may be due to the lower electronegativity and higher polarizability of the thio-compounds, allowing a higher delocalization of the phenolate negative charge. Also the electronegativity of the ring O-atom is higher than that of the N–CH$_3$ group, thus allowing a higher stabilization of the corresponding phenolate negative charges.

From the species distribution curves of the compounds at different pH conditions (see Fig. S1 of Supplementary Material†), it can be seen that for all the compounds the neutral HL species are predominant at the physiological pH: *ca* 95% for maltol, 88% for thiomaltol and 100% for both DMHP and DMHTP. This is a relevant feature in terms of membrane-crossing capacity.

The lipo/hydrophilic character of the ligands was also assessed through calculation of the corresponding partition coefficients (log P) between 1-octanol and a tris-buffered (pH = 7.4) aqueous solution. Analysis of log P values (see Table 1) clearly shows that the O-heterocyclic compounds, maltol (log P = −0.04) and thiomaltol (log P = 0.54), have higher lipophilic character then the corresponding N-heterocycles,

DMHTP (log P = −0.59) and DMHP (log P = −0.85). DMHP presents a partition coefficient slightly below the limit usually accepted for hydrophilic compounds (log P < −1). The thiocarbonylic compounds are more lipophilic than the corresponding carbonylic analogues. This can mainly be due to the fact that the sulfur atom, being less electronegative and more polarizable than the oxygen atom, can establish weaker H-bond interactions with water molecules.

3.2 Complexation studies

The global formation constants calculated for the studied Zn(II) complexes are indicated in Table 1, which also includes some reported values for maltol and DMHP. For both the oxo and thio compounds, the mono- and bis-chelate complexes were found in our equilibrium model, corresponding to a (O,O)/(O,S) or a [2 × (O,O)]/[2 × (O,S)] coordination mode (see Fig. 1). Fig. 1 shows that, under the experimental methanol–aqueous conditions, the bis-chelate species predominates above pH *ca* 5–7. Moreover, for all the compounds at pH > 7.0, the ZnL$_3$ species, corresponding to a 6 coordination number for Zn(II), was also detected and the corresponding values are indicated in Table 1 for maltol, thiomaltol and DMHTP. In the case of the Zn(II)/DMHP system, the formation constant for the tris-chelate complex could be estimated (log β *ca* 15.5) but it appears only at very low percentage (<5%) under 1 : 4 metal-to-ligand stoichiometric conditions, and so it is not depicted in Table 1. Besides the tris-chelate complex species found for all cases, mixed hydroxo species ZnL$_2$OH were also admitted in the complexation model except for thiomaltol (due to earlier precipitation problems).

A comparative analysis of the zinc(II)-binding affinity of the ligands, based on the overall stability constants, or more accurately on the pZn values (at physiological pH 7.4, C_L/C_{Zn} = 10, C_{Zn} = 10^{-6} M, see Table 1), indicates that Zn(II) is more strongly bound by the softer O,S-donor ligands (thiomaltol and DMHTP) than the harder O,O-analogues (maltol and DMHP). The pZn values follow the order (indicated by the ligands) DMHTP > thiomaltol > DMHP > maltol, which reasonably agrees with the stability both of the mono and bis complexes, but not with the basicity of the coordinating donors. So the electronic stabilization through the N-ring that explains the higher basicity of the pyridinone relative to the pyrone derivatives is less relevant in the Zn-complex stability, which seems to be over-passed by the type of coordinating atoms, namely the π character of the thione.

The species distribution curves for the Zn(II)–ligand systems shown in Fig. 1 also indicate that, at the physiological pH, the percentage of neutral species (ZnL$_2$) decreases according to the following trend order: DMHTP (98%) > thiomaltol (93%) > DMHP (90%) > maltol (73%). It can be seen that the percent formation of the neutral ZnL$_2$ species is extremely high in all systems except for Zn(II)/maltol. In this last case, the simultaneous presence of the charged ZnL complex can be associated with a reduction of permeability and/or an increase of metal ion release, features of potential biological relevance. The above-mentioned trend follows the pZn value, but it does not correlate with the percentage of HL formation at physiological pH for the ligands (DMHTP ≈ DMHP > maltol > thiomaltol), which suggests

Fig. 1 Species distribution diagrams for the Zn(II)–L 1:4 systems: L = maltol (a), L = thiomaltol (b), L = DMHP (c) and L = DMHTP (d). $C_L = 2 \times 10^{-3}$ M.

that the lipophilicity order of the zinc complexes eventually does not parallel that of the ligands.

Therefore, the thio-derivatives seem to present two major advantages, as compared with the oxo-derivatives, namely the higher stability of the zinc complexes and also the higher lipophilicity of the ligands and complexes, two important requirements to facilitate the zinc-complex transport across apolar membranes

The solution Mo(VI) complexation with the same set of ligands was recently reported[20] and the respective stability constants are also included in Table 1. The concentration distribution curves of the Mo complex species at a 2:1 ligand-to-metal ion molar concentration ratio (see Fig. S2 of Supplementary Material†) showed that, under the experimental methanol–aqueous conditions, the bis-chelated species (MoO_2L_2) predominate below pH 4–5 and above these pH values they become decomposed through the formation of trioxo-molybdenum mono-chelate complexes (MoO_3L).[20] Moreover, both thiomaltol and DMHTP retard the formation of MoO_4^{2-} to higher pH values (≥ 7) than those of the analogous oxo complexes. Thus, at the physiological pH there is a higher percent formation of MoO_3L for the thio-compounds: *ca* 90% for thiomaltol and 60% for DMHTP; *ca* 52% for maltol and 5% for DMHP.

Analysis of the pMo values in Table 1 shows that the softer *O,S*-donor ligands (thiomaltol and DMHTP) have a slightly higher affinity for the Mo(VI) than the harder *O,O*-analogues. However this metal–ligand affinity difference between the thio- and the oxo-derivatives is much more feeble for Mo(VI)– than the corresponding Zn(II)–ligand systems.

3.3 *In vitro* insulin mimetic activities of Zn and Mo complexes

Insulin-mimetic activities of eight Zn and Mo complexes and their ligands were estimated by *in vitro* experiments, in which

the inhibition of free fatty acid (FFA) release from isolated rat adipocytes treated with epinephrine was compared with the activity of $ZnSO_4$ (positive control).

Fig. 2A shows the effects of the Zn complexes on the FFA release, in comparison with that of $ZnSO_4$, and the apparent IC_{50} values are included in Table 2. Three Zn complexes exhibited concentration-dependency release in the range of 0.1–0.5 mM. On the basis of IC_{50} values, $Zn(DMHP)_2$ was found to have low activity as insulin-mimics compared with $ZnSO_4$. On the other hand, $Zn(thiomaltol)_2$ shows very high insulin-mimetic activity compared with $ZnSO_4$. We could not evaluate the insulin-mimetic activity of $Zn(DMHTP)_2$ because it had very high lipophilicity. Thus, we evaluated the insulin mimetic activity by using $Zn(DMHTP)_2$ in a DMSO suspension solution.

In order to aid the further rationalization of the activity of the zinc complexes herein studied, we tried to identify eventual relationships between the *in vitro* insulin-mimetic activity and the lipophilicity of the ligands in the Zn(II) complexes as well as the chelating affinity of the ligands. Therefore, the pIC_{50} values ($-\log IC_{50}$) on FFA release were plotted against the partition coefficients (log P) of the ligands and the pZn of the complexes (see Fig. 3).

Analysis of Fig. 3 shows the existence of some correlation trend (although this conclusion is hampered by reduced number of points) between the insulin-mimetic activity of the Zn(II) complexes expressed as pIC_{50} ($-\log IC_{50}$), the partition coefficient of the correspondent ligands (log P) and also the zinc-chelating affinity of the ligands (pZn). Among the three complexes bioassayed, $Zn(thiomaltol)_2$ exhibited the highest values for the insulin-mimetic activity as well as for the partition coefficient (log P = 0.54) and the chelating affinity (pZn = 7.9). These results suggest that the insulin-mimetic active sites of Zn(II) are mainly in the cells. The results are also supported by Zn uptake and the following translocation of glucose transporter

Fig. 2 Inhibitory effects of (A) ZnSO$_4$ and new Zn complexes and (B) MoO$_2$ and new Mo complexes on FFA release from rat adipocytes treated with epinephrine; b (blank) and c (control) are cells only and cells plus epinephrine, respectively. Data are expressed as the means $\pm$ SDs for three experiments.

Table 2 Estimated inhibitory effects (IC$_{50}$ values) of some metal complexes on FFA release from rat adipocytes treated with epinephrine

Complex	IC$_{50}$ value/mM
ZnSO$_4$	0.518 ± 0.045
	1.00 ± 0.07^a
Zn(maltol)$_2$	0.380 ± 0.062
	0.54 ± 0.07^a
Zn(DMHP)$_2$	1.900 ± 0.041
Zn(thiomaltol)$_2$	0.0033 ± 0.0042
Zn(DMHTP)$_2$	nd*
Zn(ethylmaltol)$_2$	0.44 ± 0.05^a
MoO$_2$	None
MoO$_2$(maltol)$_2$	None
MoO$_2$(DMHP)$_2$	None
MoO$_2$(thiomaltol)$_2$	43.6 ± 21.1
MoO$_2$(DMHTP)$_2$	20.4 ± 6.3
VOSO$_4$	1.00^b
VO(ethylmaltol)$_2$	3.46^c
VO(DMHP)$_2$	1.36^c

^{a} Ref. 31; ^{b} ref. 35; ^{c} ref. 37; *nd (incapable evaluation).

Fig. 3 Trend relationship between the insulin-mimetic activity (pIC$_{50}$) values of the Zn(II) complexes, chelating affinity (pZn, ■) and the lipophilicity of the corresponding ligands (log P, ▲).

(GLUT4) in the 3T3-L1 adipocytes, which are treated with other types of Zn complexes such as Zn-allixin (with Zn(O$_4$) coordination mode)[33] and Zn-thioallixin-N-methyl and Zn-1-oxy-2-puridine-thiolate (with Zn(S$_2$O$_2$) coordination mode).[34]

The Mo(VI)-complexes with the herein reported ligands were also *in vitro* assayed for their insulin-mimetic activity based on their effect over the FFA release from rat adipocytes treated with epinephrine, in comparison with that of MoO$_2$ (see Fig. 2B). Analysis of IC$_{50}$ values indicated for the Mo complexes unexpectedly lower activities as insulin-mimics (see Table 2) than expected values based on previous results.[1] The similarly low insulin mimetic activity obtained for the

Mo(VI) complexes may be related to the high percentage of hydrolytic processes occurring at the physiological pH, otherwise also in agreement with the closely related pMo values. Apparently, the same reason stands for the lower dependency of the activity on the complex strength and on the lipophilicity of the ligand. Nevertheless, some insulin-mimetic activity could be measured for the thio-compounds (thiomaltol and DMHTP), in opposition to the oxo-analogues.

The set of *in vitro* results obtained for the zinc complexes seem to evidence that pyrone complexes present an enhanced mimetic activity as compared with the corresponding pyridinone complexes and that complexes with S_2O_2 coordination mode show higher activity than those with O_4 coordination mode. Table 2 also contains literature data for two ionic complexes (ZnSO$_4$,[31] and VOSO$_4$[35]), which are only sparingly absorbed in intestines, as well as for zinc and vanadium complexes of FDA-approved food additives, such as maltol (BMOV is already introduced in clinical trials with humans[36]) and ethylmaltol,[31,37] besides the IC$_{50}$ value for VO(DMHP)$_2$.[37] It can be concluded that the IC$_{50}$ value herein obtained for Zn(thiomaltol)$_2$ is quite lower than those from the literature in Table 2, as well as lower than the quite recently reported highest insulin mimetic activity for *N*-hydroxy-thiazole-thione zinc and vanadium complexes (IC$_{50}$ *ca.* 0.014–0.08 mM).[18] This result is undoubtedly encouraging, even if the biological studies are only still of preliminary nature.

Since in animal models it has been reported that Zn chelation can increase the risk of developing type 1 diabetes,[38] we have decided to analyze eventual effects of the ligands on the insulin-mimetic activity of the tested complexes. Therefore, the activity of the ligands alone was also bio-assayed, under the same experimental conditions of the metal complexes. It was observed that all the four ligands had little or no effect on the insulin-minetic activity (Fig. 4).

Therefore, based on the herein performed *in vitro* studies, Zn(thiomaltol)$_2$ can be considered promising as insulin-mimetics, although implications for therapy applications are obviously only speculative at this time. When considering the development of metal complexes for the treatment of DM, one has to bear in mind the choice of the metal ion and of the coordination compounds (low-toxic and low molecular weight ligands) since chelation reduces the polarity of the metal so that the complexes are able to better permeate through lipid bilayer cell membranes than the ionic compounds. Moreover, it is necessary to have an adequate hydro/lipophilicity for transport in the serum and trans-membrane transport with minimized toxicity and to make an analysis of the complex stability both *in vitro* and *in vivo* to avoid metal ion release by ligand exchange, redox processes or metabolic changes of the complex. Questions such as the role, the toxicity and the biological activity of the ligand as well as the quantity of metal ion internalized must be answered, but these issues have already been fully discussed in previous papers.[1,2,10]

The main reasons for pharma companies showing such adverse interest on vanadium compounds with high potential in oral treatment of DM seems to be the vanadate toxicity and the possible aerial oxidation of many vanadium(IV) compounds with concomitant changes in their outer appearance. Therefore,

Fig. 4 Inhibitory effects of the ligands on FFA release from rat adipocytes treated with epinephrine. b (blank) and c (control) are cells only and cells plus epinephrine, respectively. Data are expressed as the means ± SDs for three experiments.

it seems to us that the results herein presented may provide new impetus for the future implementation of drugs based on non-toxic zinc complexes of heterocyclic low molecular weight ligands.

4. Conclusion

A set of Zn(II) and Mo(VI) complexes with 3-hydroxy-4-pyrone and –pyridinone, as well as the corresponding thione derivatives, have been assessed for their insulin-mimetic activity and solution physical-chemical properties. The thio-derivatives evidenced higher activity than the oxo-analogues and the Zn(II)–thiomaltol complex appears as the most promising compound. The *in vitro* insulin-mimetic results have been somehow supported not only by the complexation properties but also by the lipo/hydrophilic character of the ligands. In fact, the higher activity presented by the *O,S*-compounds seems to be correlated with the higher Zn(II) affinity of the corresponding ligands, as compared with the corresponding *O,O*-derivatives; on the other hand, some trend was found between the insulin-mimetic activity of the zinc complexes and the lipophilicity of the ligands. So, the insulin-mimetic activity of the reported Zn(II) complexes seems to depend both on the stability of the complex and on its permeability through the cell membrane. Concerning the Mo(VI) complexes, a much lower insulin mimetic activity was revealed for these compounds than for the zinc analogues, which may be ascribed to the somewhat lower complex forming ability of the ligands towards this metal ion, with concomitantly higher competition by hydrolytic processes.

Acknowledgements

References

1 K. H. Thompson, J. Chiles, V. G. Yuen, J. Tse, J. H. McNeill and C. Orvig, *J. Biol. Inorg. Chem.*, 2004, **9**, 683–690.
2 H. Sakurai, *Expert Opin. Drug Discovery*, 2007, **2**, 873–887.

3 K. H. Thompson, J. H. McNeill and C. Orvig, *Chem. Rev.*, 1999, **99**, 2561–2671.

4 M. Anke, *Anal. Real Acad. Nac. Farm.*, 2004, **70**, 961–999.

5 P. Trumbo, A. A. Yates, S. Schlicker and M. Poos, *J. Am. Diet. Assoc.*, 2001, **101**, 294–301.

6 J. Li, G. Elberg, D. Gefel and Y. Shechter, *Biochemistry*, 1995, **34**, 6218–6225.

7 Y. Goto, K. Kida, M. Ikeuchi, Y. Kaino and H. Matsuda, *Biochem. Pharmacol.*, 1992, **44**, 174–177.

8 A. Sigel and H. Sigel, *Molybdenum and Tungsten: Their Roles in Biological Processes*, in *Metal Ions in Biological Systems*, Marcel Dekker, New York, 2002, vol. 39, p. 810.

9 R. Hille, *Chem. Rev.*, 1996, **96**, 2757–281.

10 Y. Adachi, J. Yoshida, Y. Kodera, T. Kiss, T. Jakusch, E. A. Enyedy, Y. Yoshikawa and H. Sakurai, *Biochem. Biophys. Res. Commun.*, 2006, **351**, 165–70.

11 Z. D. Liu and R. C. Hider, *Coord. Chem. Rev.*, 2002, **232**, 151–171.

12 M. A. Santos, M. Gil, L. Gano and S. Chaves, *J. Biol. Inorg. Chem.*, 2005, **10**, 564–580.

13 M. A. Santos, *Coord. Chem. Rev.*, 2008, **252**, 1213–1224.

14 R. C. Hider, L. Ejim, P. D. Taylor, R. Gale, E. Huelns and J. B. Porter, *Biochem. Pharmacol.*, 1990, **39**, 1005–1012.

15 K. H. Thompson and C. Orvig, *J. Chem. Soc., Dalton Trans.*, 2000, 2885–2892.

16 Y. Yoshikawa, E. Uedo, H. Miyaki, H. Sakurai and Y. Koshima, *Biochem. Biophys. Res. Commun.*, 2001, **281**, 1190–1193.

17 S. L. Lord, N. A. Epstein, R. L. Paddock, C. M. Vogels, T. L. Hennigar, M. J. Zawaoroto, N. J. Taylor, W. R. Driedzic, T. L. Broderick and S. A. Wescott, *Can. J. Chem.*, 1999, **77**, 1249–1261.

18 A. Katoh, Y. Matsumura, Y. Yoshikawa, H. Yasui and H. Sakurai, *J. Inorg. Biochem.*, 2009, **103**, 567–574.

19 *Purification of Laboratory Chemicals*, ed. W. L. F. Armarego and D. D. Perrin, Butterworth-Heinemann Press, Oxford, 4th edn, 1999.

20 S. Chaves, M. Gil, S. Canário, R. Jelic, M. J. Romão, J. Trincão, E. Herdtweck, J. Sousa, C. Diniz, P. Fresco and M. A. Santos, *Dalton Trans.*, 2008, 1773–1782.

21 S. Chaves, S. M. Marques, A. Cachudo, M. A. Esteves and M. A. Santos, *Eur. J. Inorg. Chem.*, 2006, 3853–3860.

22 P. Gans, A. Sabatini and A. Vacca, *Talanta*, 1996, **43**, 1739–1753.

23 R. M. Smith and A. E. Martell, *Critical Stability Constants*, Plenum, New York, 1976, vol. 4, p. 9.

24 A. Leo, C. Hansch and D. Elkins, *Chem. Rev.*, 1971, **71**, 525–616.

25 M. Nakai, H. Watanabe, C. Fujisawa, H. Kakegawa, T. Satoh, J. Takada, R. Matsushita and H. Sakurai, *Biol. Pharm. Bull.*, 1995, **18**, 719–725.

26 B. Song, N. Aebischer and C. Orvig, *Inorg. Chem.*, 2002, **41**, 1357–1364.

27 T. Jakusch, K. Gajda-Schrantz, Y. Adachi, H. Sakurai, T. Kiss and L. Horváth, *J. Inorg. Biochem.*, 2006, **100**, 1521–1526.

28 J. A. Lewis, B. L. Tran, D. T. Puerta, E. M. Rumberger, D. N. Hendrickson and S. M. Cohen, *Dalton Trans.*, 2005, 2588–2596.

29 V. Monga, B. O. Patrick and C. Orvig, *Inorg. Chem.*, 2005, **44**, 2666–2677.

30 R. Yokel, A. K. Datta and E. G. Jackson, *J. Pharmacol. Exp. Ther.*, 1991, **257**, 100–106.

31 Y. Adachi, J. Yoshida, Y. Kodera, A. Kato, Y. Yoshikawa, Y. Kojima and H. Sakurai, *J. Biol. Inorg. Chem.*, 2004, **9**, 885–893.

32 M. A. Santos, S. Gama, J. C. Pessoa, M. C. Oliveira, I. Tóth I and E. Farkas, *Eur. J. Inorg. Chem.*, 2007, 1728–1737.

33 A. Nakayama, M. Hiromura, Y. Adachi and H. Sakurai, *J. Biol. Inorg. Chem.*, 2008, **13**, 675–684.

34 W. Basuki, M. Hiromura and H. Sakurai, *J. Inorg. Biochem.*, 2007, **101**, 692–699.

35 H. Sakurai, Y. Kojima, Y. Yoshikawa, K. Kawabe and H. Yasui, *Coord. Chem. Rev.*, 2002, **226**, 187–198.

36 D. Rehder, *Inorg. Chem. Commun.*, 2003, **6**, 604–617.

37 M. Rangel, A. Tamura, C. Fukushima and H. Sakurai, *J. Biol. Inorg. Chem.*, 2001, **6**, 128–132.

38 Y. Zheng, X.-K. Li, Y. Wang and L. Cai, *Hemoglobin*, 2008, **32**, 135–145.